

骆世忠介绍

- ✓ 杭州岸金生物科技有限公司董事总经理 及 “医健国际化” 联盟&创新中心创始合伙人，同时兼任中国医药企业管理协会国际化工作委员会执行主任。
- ✓ 23年制药行业国际市场开发及国际BD项目合作经验，曾经分别就职于两家国内上市公司并作为国际业务负责人及子公司总经理职务，成功落地10多个跨国公司/海外科研机构与本土企业的合资合作、委托加工及产品引进项目。在2019年首届博鳌亚洲论坛全球健康论坛大会（GHF），曾担任GHF组委会的学术及国际合作部总监，协助首届GHF顺利召开。
- ✓ 在23年工作中，访问过近30个国家以及全球近50家以上医药及大健康领域的公司，有丰富的制药国际项目合作及BD工作经验。
- ✓ 毕业于北京大学制药工程管理专业，工程硕士。

Leo LUO

Founder and Managing Director of Hangzhou Angine Biotech Co.,Ltd and China "Pharma and MedTech BD Alliance" & Innovation Center. Leo has 23 years of experiences of the international business development in the pharmaceutical industry, and as the project leader he once managed more than 10 global transaction deals with the models of IP license-in, JV, distribution rights granting as well as overseas investment. Before founding Angine, Leo once was the Global Head and Director of International Business Development of two Pharmaceutical public companies in China, as well as the head of Academic Exchange as well as International Affairs during the 1st Global Health Forum (GHF) of Boao Forum for Asia in 2019. Besides the position in Angine, Leo also serves as Executive Director of Internationalization Working Committee of China Pharmaceutical Enterprise Association (CPEA). Leo

graduated from Peking University and obtained the Master Degree (M.E) of Pharmaceutical Engineering.

